Search results
Showing 7786 to 7800 of 8212 results
Home Implementing NICE guidance Social care...
Home About us...
The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.
Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.
Information about NICE's gender pay gap data for the 12 months leading up to 31 March 2025.
NICE's technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
How NICE International is supporting evidence-based decision-making through the Regulatory Partnership for Growth Fund
Thousands could benefit from first immunotherapy for severe birch tree pollen allergy
We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree pollen allergies.
Find guidance, advice and information for health, public health and social care professionals.
Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.
People can comment on our guidance at specific stages in its development.
NICE's partners
NICE's past research and projects
NICE provisionally recommends leadless implantable pacemaker in draft guidance
A procedure for people with slow heart rhythms could be used more widely after it was recommended for NHS use in draft guidance.
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers Principle social workers -...